214 related articles for article (PubMed ID: 16612593)
1. Non-viral in vivo immune gene therapy of cancer: combined strategies for treatment of systemic disease.
Tangney M; Casey G; Larkin JO; Collins CG; Soden D; Cashman J; Whelan MC; O'Sullivan GC
Cancer Immunol Immunother; 2006 Nov; 55(11):1443-50. PubMed ID: 16612593
[TBL] [Abstract][Full Text] [Related]
2. In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity.
Heller L; Pottinger C; Jaroszeski MJ; Gilbert R; Heller R
Melanoma Res; 2000 Dec; 10(6):577-83. PubMed ID: 11198480
[TBL] [Abstract][Full Text] [Related]
3. Step-by-Step Immune Activation for Suicide Gene Therapy Reinforcement.
Alekseenko I; Kuzmich A; Kondratyeva L; Kondratieva S; Pleshkan V; Sverdlov E
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502287
[TBL] [Abstract][Full Text] [Related]
4. Irreversible electroporation facilitates gene transfer of a GM-CSF plasmid with a local and systemic response.
Au JT; Mittra A; Song TJ; Cavnar M; Jun K; Carson J; Gholami S; Haddad D; Gaujoux S; Monette S; Ezell P; Wolchok J; Fong Y
Surgery; 2013 Sep; 154(3):496-503. PubMed ID: 23972655
[TBL] [Abstract][Full Text] [Related]
5. Immune gene therapy as a neoadjuvant to surgical excision to control metastatic cancers.
Cashman JP; Larkin JO; Casey G; Whelan MC; Collins C; Aarons S; Tangney M; O'Sullivan GC
Cancer Lett; 2008 Apr; 262(1):94-102. PubMed ID: 18179863
[TBL] [Abstract][Full Text] [Related]
6. Effective immunotherapy of weakly immunogenic solid tumours using a combined immunogene therapy and regulatory T-cell inactivation.
Whelan MC; Casey G; MacConmara M; Lederer JA; Soden D; Collins JK; Tangney M; O'Sullivan GC
Cancer Gene Ther; 2010 Jul; 17(7):501-11. PubMed ID: 20186173
[TBL] [Abstract][Full Text] [Related]
7. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL12.
Parney IF; Farr-Jones MA; Kane K; Chang LJ; Petruk KC
Can J Neurol Sci; 2002 Aug; 29(3):267-75. PubMed ID: 12195617
[TBL] [Abstract][Full Text] [Related]
8. Local Delivery of OncoVEX
Moesta AK; Cooke K; Piasecki J; Mitchell P; Rottman JB; Fitzgerald K; Zhan J; Yang B; Le T; Belmontes B; Ikotun OF; Merriam K; Glaus C; Ganley K; Cordover DH; Boden AM; Ponce R; Beers C; Beltran PJ
Clin Cancer Res; 2017 Oct; 23(20):6190-6202. PubMed ID: 28706012
[No Abstract] [Full Text] [Related]
9. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model.
Parney IF; Petruk KC; Zhang C; Farr-Jones M; Sykes DB; Chang LJ
Hum Gene Ther; 1997 Jun; 8(9):1073-85. PubMed ID: 9189765
[TBL] [Abstract][Full Text] [Related]
10. Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas.
Parney IF; Chang LJ; Farr-Jones MA; Hao C; Smylie M; Petruk KC
J Neurooncol; 2006 May; 78(1):71-80. PubMed ID: 16718522
[TBL] [Abstract][Full Text] [Related]
11. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.
Gordon EM; Levy JP; Reed RA; Petchpud WN; Liu L; Wendler CB; Hall FL
Int J Oncol; 2008 Oct; 33(4):665-75. PubMed ID: 18813779
[TBL] [Abstract][Full Text] [Related]
12. Non-viral immune electrogene therapy induces potent antitumour responses and has a curative effect in murine colon adenocarcinoma and melanoma cancer models.
Forde PF; Hall LJ; de Kruijf M; Bourke MG; Doddy T; Sadadcharam M; Soden DM
Gene Ther; 2015 Jan; 22(1):29-39. PubMed ID: 25373914
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model.
Majumdar AS; Zolotorev A; Samuel S; Tran K; Vertin B; Hall-Meier M; Antoni BA; Adeline E; Philip M; Philip R
Cancer Gene Ther; 2000 Jul; 7(7):1086-99. PubMed ID: 10917212
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for human nasopharyngeal carcinoma by adenovirus-mediated transfer of human p53, GM-CSF, and B7-1 genes in a mouse xenograft tumor model.
Ren SP; Wang L; Wang H; Wu B; Han Y; Wang LS; Wu CT
Cancer Biother Radiopharm; 2008 Oct; 23(5):591-602. PubMed ID: 18999931
[TBL] [Abstract][Full Text] [Related]
15. Sonoporation mediated immunogene therapy of solid tumors.
Casey G; Cashman JP; Morrissey D; Whelan MC; Larkin JO; Soden DM; Tangney M; O'Sullivan GC
Ultrasound Med Biol; 2010 Mar; 36(3):430-40. PubMed ID: 20133039
[TBL] [Abstract][Full Text] [Related]
16. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
17. Improved therapeutic outcome following combination immunogene vaccination therapy in murine myeloma.
Li ZH; Wen XY; Mandelbaum S; Falcioni N; Hawley TS; Hawley RG; Stewart AK
Leuk Lymphoma; 2003 Oct; 44(10):1775-84. PubMed ID: 14692533
[TBL] [Abstract][Full Text] [Related]
18. Viral vectors in cancer immunotherapy: which vector for which strategy?
Collins SA; Guinn BA; Harrison PT; Scallan MF; O'Sullivan GC; Tangney M
Curr Gene Ther; 2008 Apr; 8(2):66-78. PubMed ID: 18393828
[TBL] [Abstract][Full Text] [Related]
19. Replication-deficient adenovirus-mediated transfer of B7-1 (CD80) cDNA induces anti-tumour immunity in isolated human lung cancer.
Iwakami SI; Setoguchi Y; Saijo Y; Azuma M; Fukuchi Y
Respirology; 2001 Jun; 6(2):135-44. PubMed ID: 11422893
[TBL] [Abstract][Full Text] [Related]
20. AAV2-mediated in vivo immune gene therapy of solid tumours.
Collins SA; Buhles A; Scallan MF; Harrison PT; O'Hanlon DM; O'Sullivan GC; Tangney M
Genet Vaccines Ther; 2010 Dec; 8():8. PubMed ID: 21172020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
